Physiotherapy Review
en POLSKI
eISSN: 2719-9665
ISSN: 2719-5139
Physiotherapy Review
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2025
vol. 29
 
Share:
Send email
Share:
Research paper

The role of gene polymorphisms (angiotensinconverting enzyme, tumor necrosis factor-alpha, and endothelial nitric oxide synthase) in the pathogenesis and treatment of chronic heart failure: Can gene polymorphism testing predict the effectiveness of physical training in cardiac rehabilitation?

Ewa Barbara Kucio
1
,
Cezary Kucio
2, 3

  1. Institute of Physiotherapy and Health Sciences, Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland
  2. Department of Internal Medicine, District Railway Hospital in Katowice, Katowice, Poland
  3. Department of Physiotherapy in Internal Diseases, Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland
Research, Physiotherapy Review, 2025, 29(2), 15-23
DOI: https://doi.org/10.5114/phr.2025.152195
Online publish date: 2025/06/26
Article file
- art2_2_2025.pdf  [0.25 MB]
Get citation
 
PlumX metrics:
 
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku. Kardiol Pol. 2016; 74 (10): 1037–1047.
2. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J. 1997; 18 (2): 208–225.
3. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42 (36): 3599–726. Erratum in: Eur Heart J. 2021; 42 (48): 4901.
4. Bissessor N, White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag. 2007; 3 (4): 425–430.
5. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86 (4): 1343–1346.
6. Tokunaga S, Tsuji H, Nishiue T, Yamada K, Miyasaka Y, Saitou D, et al. Lower mortality in patients with the DD genotype of the angiotensin-converting enzyme gene after acute myocardial infarction. Acta Cardiol. 2001; 56 (6): 351–355.
7. Ohmichi N, Iwai N, Nakamura Y, Kinoshita M. The genotype of the angiotensin-converting enzyme gene and global left ventricular dysfunction after myocardial infarction. Am J Cardiol. 1995; 76 (5): 326–329.
8. Amara A, Mrad M, Sayeh A, Lahideb D, Layouni S, Haggui A, et al. The effect of ACE I/D polymorphisms alone and with concomitant risk factors on 22Physiotherapy Review | Volume XXIX Issue 2/2025 coronary artery disease. Clin Appl Thromb Hemost.2018; 24 (1): 157–163.
9. Bahramali E, Rajabi M, Jamshidi J, Mousavi SM, Zarghami M, Manafi A, et al. Association of ACE gene D polymorphism with left ventricular hypertrophy in patients with diastolic heart failure: a case-control study. BMJ Open. 2016; 6 (2): e010282.
10. Poorzand H, Fazeli B, Khajavi O, Gholoobi A, Keihanian F, Morovatdar N. Association of polymorphisms of renin angiotensin system and endothelial nitric oxide synthase genes with premature cardiovascular disease in an Iranian population. BMC Cardiovasc Disord. 2023; 23 (1): 254.
11. Yuan Y, Meng L, Zhou Y, Lu N. Genetic polymorphism of angiotensin-converting enzyme and hypertrophic cardiomyopathy risk: a systematic review and meta-analysis. Medicine (Baltimore). 2017; 96 (48): e8639.
12. Ohmichi N, Iwai N, Maeda K, Shimoike H, Nakamura Y, Izumi M, et al. Genetic basis of left ventricular remodeling after myocardial infarction. Int J Cardiol. 1996; 53 (3): 265–272.
13. Schut AF, Bleumink GS, Stricker BH, Hofman A, Witteman JC, Pols HA, et al. Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur Heart J. 2004; 25 (23): 2143–2148.
14. Bai Y, Wang L, Hu S, Wei Y. Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis. Mol Cell Biochem. 2012; 361 (1–2): 297–304.
15. Gorący I, Gorący A, Kaczmarczyk M, Rosik J, Lewandowska K, Ciechanowicz A. The genetic variants in the renin-angiotensin system and the risk of heart failure in Polish patients. Genes (Basel). 2022; 13 (7): 1257.
16. Guo M, Guo G, Ji X. Genetic polymorphisms associated with heart failure: a literature review. J Int Med Res. 2016; 44 (1): 15–29.
17. Costa AM, Silva AJ, Garrido ND, Louro H, de Oliveira RJ, Breitenfeld L. Association between ACE D allele and elite short distance swimming. Eur J Appl Physiol. 2009; 106 (6): 785–790.
18. Gard PR. Implications of the angiotensin converting enzyme gene insertion/deletion polymorphism in health and disease: a snapshot review. Int J Mol Epidemiol Genet. 2010; 1 (2): 145–157.
19. De Mello Costa MF, Slocombe R. The use of angiotensin-I converting enzyme I/D genetic polymorphism as a biomarker of athletic performance in humans. Biosensors (Basel). 2012; 2 (4): 396–404.
20. Juffer P, Furrer R, González-Freire M, Santiago C, Verde Z, Serratosa L, et al. Genotype distributions in top-level soccer players: a role for ACE? Int JSports Med. 2009; 30 (5): 387–392.
21. Min SK, Takahashi K, Ishigami H, Hiranuma K, Mizuno M, Ishii T, et al. Is there a gender difference between ACE gene and race distance? Appl Physiol Nutr Metab. 2009; 34 (5): 926–932.
22. Cieszczyk P, Krupecki K, Maciejewska A, Sawczuk M. The angiotensin converting enzyme gene I/D polymorphism in Polish rowers. Int J Sports Med.2009; 30 (8): 624–627.
23. Goh KP, Chew K, Koh A, Guan M, Wong YS, Sum CF. The relationship between ACE gene ID polymorphism and aerobic capacity in Asian rugby players. Singapore Med J. 2009; 50 (10): 997–1003.
24. Abraham MR, Olson LJ, Joyner MJ, Turner ST, Beck KC, Johnson BD. Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure. Circulation. 2002; 106 (14): 1794–1799.
25. Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, Arumanayagam M, et al. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. Am Heart J. 1999; 137 (4 Pt 1): 653–657.
26. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan GA, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation. 2001; 103 (12): 1644–1648.
27. Pinto YM, van Gilst WH, Kingma JH, Schunkert H; Captopril and Thrombolysis Study Investigators. 23 Physiotherapy Review | Volume XXIX Issue 2/2025Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. J Am Coll Cardiol. 1995; 25 (7): 1622–1626.
28. McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, Mathier M, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol.2004; 44 (10): 2019–2026.
29. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E. Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail. 2006; 8 (3): 270–274.
30. Bradham WS, Moe G, Wendt KA, Scott AA, Konig A, Romanova M, et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002; 282 (4): H1288–1295.
31. Opielak G, Powrózek T, Skwarek-Dziekanowska A, Sobieszek G, Rahnama-Hezavah M, Małecka-Massalska T. Effect of polymorphism rs1799964 in TNF-α gene on survival in depressive patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2021; 25 (21): 6652–6659.
32. Bielecka-Dabrowa A, Sakowicz A, Pietrucha T, Misztal M, Chruściel P, Rysz J, et al. The profile of selected single nucleotide polymorphisms in patients with hypertension and heart failure with preserved and mid-range ejection fraction. Sci Rep. 2017; 7 (1): 8974.
33. Dzida G, Biłan A, Hanzlik J. Tumor necrosis factor alpha (TNF-α) gene G-308A polymorphism in patients with type 2 diabetes [Polimorfizm G-308A genu czynnika martwicy guza alfa (TNF-α) u chorych na cukrzycę typu 2]. Diabetol Prakt. 2001; 2: 267–272. Polish.
34. Leońska-Duniec A, Ficek K, Świtała K, Cięszczyk P. Association of the TNF-α -308G/A polymorphism with lipid profile changes in response to aerobic training program. Biol Sport. 2019; 36 (3): 291–296.
35. McNamara DM, Holubkov R, Postava L, Ramani R, Janosko K, Mathier M, et al. Effect of the Asp298 variant of endothelial nitric oxide synthase on survival for patients with congestive heart failure. Circulation. 2003; 107 (12): 1598–1602.
36. Terzi S, Emre A, Yesilcimen K, Yazıcı S, Erdem A, Sadik Ceylan U, et al. The endothelial nitric oxide synthase (NOS3-786T>C) genetic polymorphism in chronic heart failure: effects of mutant -786C allele on long-term mortality. Acta Cardiol Sin. 2017; 33 (4): 420–428.
37. Augeri AL, Tsongalis GJ, Van Heest JL, Maresh CM, Thompson PD, Pescatello LS. The endothelial nitric oxide synthase -786 T>C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure. Atherosclerosis. 2009; 204 (2): e28–34.
38. Negrao MV, Alves CR, Alves GB, Pereira AC, Dias RG, Laterza MC, et al. Exercise training improves muscle vasodilatation in individuals with T786C polymorphism of endothelial nitric oxide synthase gene. Physiol Genomics. 2010; 42A (1): 71–77.
39. Jaishankar T, Shivasekar M, Vinodhini VM. Endothelial nitric oxide synthase T-786C and G-894T gene polymorphisms: a risk assessment of coronary heart disease. J Assoc Physicians India. 2023; 71 (9): 45–50.
40. Cozma A, Fodor A, Orasan OH, Vulturar R, Samplelean D, Negrean V, et al. Pharmacogenetic implications of eNOS polymorphisms (Glu298Asp, T786C, 4b/4a) in cardiovascular drug therapy. In Vivo. 2019; 33 (4): 1051–1058.
PUBLISHER

Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.